NASDAQ:DTIL   Precision BioSciences, Inc.
Hi, today we are going to talk about Precision BioSciences and its current landscape.

Precision BioSciences, the genome editing company has received attention lately as the Cancer - Drug Race heats up, in the middle a day of the announcements of a $5.2 billion total in Acquisitions by big names of the pharmaceuticals sector, such as Merck & Co. and Sanofi, that had made strategic movements on the oncology sector. Precision BioSciences has been crushed, after unveiled early-stage CAR T data in NHL, the data puts the company behind of competition, as the sector becomes more and more competitive.


Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.

Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.